AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39614837 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual congestion (CCS ≥1) at day 5 after admission
Number of subjects: 5900
Study 39614837 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual congestion (CCS ≥3) at day 5 after admission
Number of subjects: 5900
Study 39614852 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-QCA-assisted PCI
Number of subjects: 400
Study 39614852 — intervention group
Group type: COMPARATOR
Intervention: OCT-guided PCI
Number of subjects: 400
Study 39614857 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses (VR-G) - patients watched a 360-degree video with nature sounds before surgery
Number of subjects: 90
Study 39614857 — intervention group
Group type: COMPARATOR
Intervention: Control group - no specific intervention mentioned
Number of subjects: 90
Study 39614865 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression tights ON (AM-ON)
Number of subjects: 26
Study 39614865 — intervention group
Group type: COMPARATOR
Intervention: Compression tights OFF (AM-OFF)
Number of subjects: 26
Study 39614865 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression tights ON (AM-ON) during medications
Number of subjects: 26
Study 39614865 — intervention group
Group type: COMPARATOR
Intervention: Compression tights OFF (AM-OFF) during medications
Number of subjects: 26
Study 39614866 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote evaluation of cardiac implantable electronic devices (CIEDs)
Number of subjects: 34
Study 39614866 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote evaluation of CIEDs
Number of subjects: 34
Study 39614986 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic cartilage-repair implant (BiCRI)
Number of subjects: 92
Study 39614986 — intervention group
Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 92
Study 39615031 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted microwave ablation (TMA) using a 12 W very low-loss microwaves ablation system guided by 3D ultrasound/MRI fusion imaging
Number of subjects: 11
Study 39615031 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted microwave ablation (TMA)
Number of subjects: 11
Study 39615342 — intervention group
Group type: EXPERIMENTAL
Intervention: COVIVAC 3 μg
Number of subjects: 374
Study 39615342 — intervention group
Group type: EXPERIMENTAL
Intervention: COVIVAC 6 μg
Number of subjects: 374
Study 39615342 — intervention group
Group type: COMPARATOR
Intervention: VAXZEVRIA
Number of subjects: 374
Study 39615398 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month intervention integrating a Diabetes Prevention Program-based behavioral weight loss treatment with problem-solving therapy for depression
Number of subjects: 409
Study 39615398 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 409
Study 39615412 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-PCI
Number of subjects: 318
Study 39615412 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 318
Study 39615435 — intervention group
Group type: EXPERIMENTAL
Intervention: eNose measurements
Number of subjects: 160
Study 39615484 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab plus anlotinib
Number of subjects: 40
Study 39615497 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) to the primary tumour (50-54 Gy in three to five fractions) followed by standard radiotherapy (up to 60 Gy in 30 2 Gy fractions) to the involved lymph nodes with concurrent platinum doublet chemotherapy (either paclitaxel 50 mg/m2).
Number of subjects: 61
Study 39615497 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation durvalumab (immunotherapy).
Number of subjects: 61
Study 39615497 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events.
Number of subjects: 61
Study 39615497 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related deaths.
Number of subjects: 61
Study 39615502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled-BENRA (benralizumab with or without prednisolone)
Number of subjects: 158
Study 39615502 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone alone (PRED group)
Number of subjects: 158
Study 39615582 — intervention group
Group type: EXPERIMENTAL
Intervention: SurVeil PCB
Number of subjects: 446
Study 39615582 — intervention group
Group type: COMPARATOR
Intervention: IN.PACT Admiral PCB
Number of subjects: 446
Study 39615596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern A (higher baseline, amplitude, frequency, and damping)
Number of subjects: 159
Study 39615596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern A
Number of subjects: 159
Study 39615618 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT; acetyl-salicylic-acid 100mg plus clopidogrel 75mg daily)
Number of subjects: 62
Study 39615618 — intervention group
Group type: COMPARATOR
Intervention: Single antiplatelet (SAPT; clopidogrel 75mg) plus DOAC (rivaroxaban 15mg)
Number of subjects: 62
Study 39615618 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 62
Study 39615802 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized metric for histologic airway mucosa assessments
Number of subjects: 0
Study 39615802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue collection methods and histological assessment methods
Number of subjects: 0
Study 39615889 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 weekly IA injection of 5 mL PRP for 3 weeks
Number of subjects: 210
Study 39615889 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 210
Study 39615886 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 88
Study 39615886 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (per year)
Number of subjects: 88
Study 39615936 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based training intervention
Number of subjects: 60
Study 39615936 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 39616189 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase treatment
Number of subjects: 616
Study 39616365 — intervention group
Group type: EXPERIMENTAL
Intervention: FallFitness exercise program (multicomponent exercise program delivered weekly for 8 weeks)
Number of subjects: 101
Study 39616365 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 101
Study 39616375 — intervention group
Group type: EXPERIMENTAL
Intervention: Friends in Nature intervention
Number of subjects: 0
Study 39617017 — intervention group
Group type: EXPERIMENTAL
Intervention: CTX130 (volamcabtagene durzigedleucel)
Number of subjects: 39
Study 39617017 — intervention group
Group type: EXPERIMENTAL
Intervention: CTX130 (volamcabtagene durzigedleucel) at dose level 3 and higher
Number of subjects: 39
Study 39617030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human prourokinase (15 mg bolus followed by 20 mg infusion within 30 min)
Number of subjects: 1552
Study 39617030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human prourokinase
Number of subjects: 1552
Study 39617030 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alteplase (0.9 mg per kg, maximum dose 90 mg; 10% bolus followed by remainder as infusion over 60 min)
Number of subjects: 1552
Study 39617030 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alteplase
Number of subjects: 1552
Study 39617060 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg up to every 16 weeks after 4 initial doses every 4 weeks (Q4W)
Number of subjects: 1329
Study 39617060 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg every 8 weeks after 3 initial doses given every 4 weeks (Q4W)
Number of subjects: 1329
Study 39617060 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab
Number of subjects: 1329
Study 39617060 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 1329
Study 39617145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine (MIRV) 6 mg/kg adjusted ideal body weight every 3 weeks until progressive disease, unacceptable toxicity, withdrawal of consent, or death
Number of subjects: 79
Study 39617145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine (MIRV)
Number of subjects: 79
Study 39617302 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-reduced high-protein diet (CRHP, C/P/F = 30/30/40 E%)
Number of subjects: 102
Study 39617302 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric carbohydrate-reduced high-protein diet (CRHP)
Number of subjects: 102
Study 39617302 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes diet (CD, C/P/F = 50/17/33 E%)
Number of subjects: 102
Study 39617410 — intervention group
Group type: EXPERIMENTAL
Intervention: Apollo wearable device
Number of subjects: 25
Study 39617464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Disorder (BD)
Number of subjects: 106
Study 39617464 — intervention group
Group type: COMPARATOR
Intervention: Unipolar Disorder (UD)
Number of subjects: 106
Study 39617530 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 905677 at 2.8 mg/kg every 3 weeks
Number of subjects: 37
Study 39617530 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 905677 at 3.6 mg/kg every 3 weeks
Number of subjects: 37
Study 39617530 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 905677 (various doses)
Number of subjects: 37
Study 39617535 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 905681 (1.0, 2.5, 5.0, 7.0, and 8.5 mg/kg)
Number of subjects: 21
Study 39617535 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 905681
Number of subjects: 21
Study 39617673 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxylanthanum carbonate 1000 mg three times/day
Number of subjects: 80
Study 39617673 — intervention group
Group type: COMPARATOR
Intervention: Lanthanum carbonate (LC) 1000 mg three times/day
Number of subjects: 80
Study 39617826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinostamustine, 100 mg/m²
Number of subjects: 10
Study 39617826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinostamustine, RP2D (recommended Phase II dose)
Number of subjects: 10
Study 39618085 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy before and after ACL reconstruction (ACLR)
Number of subjects: 0
Study 39618085 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy after ACL reconstruction (ACLR) only
Number of subjects: 0
Study 39618085 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation and other preoperative variables
Number of subjects: 0
Study 39618097 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 47
Study 39618097 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + Probiotics (HP)
Number of subjects: 47
Study 39618097 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (H)
Number of subjects: 47
Study 39618097 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 47
Study 39618195 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment according to subtype (esomeprazole for epigastric pain syndrome; itopride for postprandial distress syndrome; itopride with possible switch to esomeprazole at week 4)
Number of subjects: 180
Study 39618195 — intervention group
Group type: COMPARATOR
Intervention: Empirical proton pump inhibitor (esomeprazole only)
Number of subjects: 180
Study 39618195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 180
Study 39618204 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administered before extubation
Number of subjects: 0
Study 39618204 — intervention group
Group type: COMPARATOR
Intervention: Control group (no propofol)
Number of subjects: 0
Study 39618256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks on background intranasal corticosteroids
Number of subjects: 724
Study 39618256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study 39618477 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous oral progesterone (200 mg twice daily)
Number of subjects: 0
Study 39618477 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 39618688 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intervention
Number of subjects: 0
Study 39618866 — intervention group
Group type: EXPERIMENTAL
Intervention: Low lung compliance (≤23.8 mL/cmH2O)
Number of subjects: 141
Study 39618866 — intervention group
Group type: COMPARATOR
Intervention: Higher lung compliance (above 23.8 mL/cmH2O)
Number of subjects: 141
Study 39619400 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth-generation M-TEER system
Number of subjects: 95
Study 39619495 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART-U intervention (12-week intensive educational sessions and 12-week remotely accessed telephone follow-up)
Number of subjects: 188
Study 39619495 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (eTAU) control group
Number of subjects: 188
Study 39619495 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART-U intervention
Number of subjects: 188
Study 39620046 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) 160 mg every 2 weeks (Q2W; Weeks 0-10) then 320 mg Q4W (Weeks 12-44)
Number of subjects: 76
Study 39620046 — intervention group
Group type: COMPARATOR
Intervention: Certolizumab pegol (CZP) 400 mg Q2W (Weeks 0-4), then 200 mg Q2W (Weeks 6-10), 400 mg Q4W (Weeks 12-44)
Number of subjects: 76
Study 39620046 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ)
Number of subjects: 76
Study 39620046 — intervention group
Group type: COMPARATOR
Intervention: Certolizumab pegol (CZP)
Number of subjects: 76
Study 39620153 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with standard pharmacological treatment (EG)
Number of subjects: 60
Study 39620153 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacological treatment with placebo acupuncture (CG)
Number of subjects: 60
Study 39620153 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EG)
Number of subjects: 60
Study 39620153 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture (CG)
Number of subjects: 60
Study 39620201 — intervention group
Group type: EXPERIMENTAL
Intervention: PNET HR+5 regimen (intensive pediatric chemotherapy)
Number of subjects: 18
Study 39620432 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy
Number of subjects: 3840
Study 39620432 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 3840
Study 39620470 — intervention group
Group type: EXPERIMENTAL
Intervention: User-operated audiometry (UAud group)
Number of subjects: 215
Study 39620470 — intervention group
Group type: COMPARATOR
Intervention: Traditional audiometry (control group)
Number of subjects: 215
Study 39621093 — intervention group
Group type: EXPERIMENTAL
Intervention: GU RMS
Number of subjects: 599
Study 39621093 — intervention group
Group type: EXPERIMENTAL
Intervention: LR GU RMS
Number of subjects: 599
Study 39621100 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week online exposure-based intervention
Number of subjects: 0
Study 39621100 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39621103 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 IU/day of vitamin D
Number of subjects: 2271
Study 39621103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2271
Study 39621227 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 955
Study 39621320 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisetting air purification
Number of subjects: 79
Study 39621320 — intervention group
Group type: COMPARATOR
Intervention: Sham purification
Number of subjects: 79
Study 39621340 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic text message refill reminders
Number of subjects: 9501
Study 39621340 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nudge text refill reminders
Number of subjects: 9501
Study 39621340 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nudge text refill reminders plus a fixed-message chatbot
Number of subjects: 9501
Study 39621340 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 9501
Study 39621340 — intervention group
Group type: COMPARATOR
Intervention: Generic text message refill reminders vs Usual care
Number of subjects: 9501
Study 39621340 — intervention group
Group type: COMPARATOR
Intervention: Behavioral nudge text refill reminders vs Usual care
Number of subjects: 9501
Study 39621340 — intervention group
Group type: COMPARATOR
Intervention: Behavioral nudge text refill reminders plus a fixed-message chatbot vs Usual care
Number of subjects: 9501
Study 39621341 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARING Choices intervention
Number of subjects: 22949
Study 39621341 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 22949
Study 39621368 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Number of subjects: 449
Study 39621368 — intervention group
Group type: COMPARATOR
Intervention: Health Education Control
Number of subjects: 449
Study 39621369 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth of color (Black and Latinx)
Number of subjects: 0
Study 39621369 — intervention group
Group type: COMPARATOR
Intervention: White youth
Number of subjects: 0
Study 39621372 — intervention group
Group type: EXPERIMENTAL
Intervention: HOLA intervention (n = 30)
Number of subjects: 60
Study 39621372 — intervention group
Group type: COMPARATOR
Intervention: Enhanced psychoeducation (Control)
Number of subjects: 60
Study 39621373 — intervention group
Group type: EXPERIMENTAL
Intervention: Online, coached mindfulness intervention
Number of subjects: 111
Study 39621373 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 111
Study 39621405 — intervention group
Group type: EXPERIMENTAL
Intervention: E4W mobile health app
Number of subjects: 32
Study 39621405 — intervention group
Group type: COMPARATOR
Intervention: Control group using default phone camera
Number of subjects: 32
Study 39621424 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 100
Study 39621424 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 100
Study 39621640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for mortality
Number of subjects: 132145
Study 39621640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for myocardial infarction
Number of subjects: 132145
Study 39621640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for pneumonia
Number of subjects: 132145
Study 39621640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for acute renal failure
Number of subjects: 132145
Study 39621640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for readmission
Number of subjects: 132145
Study 39621640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for venous thromboembolism
Number of subjects: 132145
Study 39621640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for sepsis or septic shock
Number of subjects: 132145
Study 39621640 — intervention group
Group type: EXPERIMENTAL
Intervention: Complication rates for bleeding requiring transfusion
Number of subjects: 132145
Study 39621640 — intervention group
Group type: EXPERIMENTAL
Intervention: Complication rates for hospital readmission
Number of subjects: 132145
Study 39621640 — intervention group
Group type: EXPERIMENTAL
Intervention: Complication rates for cardiac arrest and acute renal failure
Number of subjects: 132145
Study 39621728 — intervention group
Group type: EXPERIMENTAL
Intervention: DMC laser diode (λ = 808 nm), 4J per point, 100mW of power, 1,016W/cm2, 8 sites in the vulvar region, four consecutive applications, weekly.
Number of subjects: 60
Study 39621728 — intervention group
Group type: COMPARATOR
Intervention: Placebo (laser turned off)
Number of subjects: 60
Study 39621979 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine (n = 15)
Number of subjects: 46
Study 39621979 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar dexmedetomidine (n = 31)
Number of subjects: 46
Study 39622021 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Remote Interpreting (VRI) during medical appointments
Number of subjects: 216
Study 39622021 — intervention group
Group type: COMPARATOR
Intervention: Standard communication tools (informal interpretation, lip- or note-reading, mobile phone contact with interpreters) during medical appointments
Number of subjects: 216
Study 39622165 — intervention group
Group type: EXPERIMENTAL
Intervention: AN+AD (Brentuximab Vedotin, Nivolumab, Doxorubicin, Dacarbazine)
Number of subjects: 57
Study 39622410 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day) plus Ramucirumab (10 mg/kg every two weeks)
Number of subjects: 449
Study 39622410 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Erlotinib (150 mg/day)
Number of subjects: 449
Study 39622468 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-led intervention program (PLAN)
Number of subjects: 576
Study 39622468 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 576
Study 39622570 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy with personality assessment using the Big Five Inventory, General Anxiety Disorder 7-item scale, and Patient Health Questionnaire 9-item Depression Scale.
Number of subjects: 322
Study 39622570 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy with personality assessment.
Number of subjects: 322
Study 39622571 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-driven platform for CAD assessment using CCTA
Number of subjects: 4196
Study 39622578 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimisation to contemporary HFrEF medical therapy with sacubitril/valsartan
Number of subjects: 49
Study 39622578 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49